Shanghai Kaibao Pharmaceutical Co. Ltd. | Ownership
Companies that own Shanghai Kaibao Pharmaceutical Co. Ltd.
China Investment Corp. (Investment Management)
31,053,880
3.88%
0
0.07%
03/31/2018
E Fund Management Co., Ltd.
14,533,275
1.81%
-11,900
0.07%
12/31/2017
China Southern Asset Management Co., Ltd.
3,753,024
0.47%
-19,384,440
0.03%
03/31/2018
Guotai Junan Allianz Fund Management Co., Ltd.
2,257,004
0.28%
-108,591
0.11%
12/31/2017
The Vanguard Group, Inc.
1,345,208
0.17%
0
0%
07/31/2018
GF Fund Management Co., Ltd.
702,423
0.09%
80,760
0.01%
12/31/2017
Morgan Stanley Huaxin Fund Management Co., Ltd.
660,990
0.08%
-530,410
0.06%
12/31/2017
Manulife TEDA Fund Management Co., Ltd.
597,100
0.08%
597,100
0.01%
12/31/2017
Tian Hong Asset Management Co., Ltd.
338,195
0.04%
62,100
0.02%
12/31/2017
CITIC-Prudential Fund Management Co., Ltd.
318,606
0.04%
184,700
0.01%
12/31/2017
| Address |
No. 88, Chengpu Road
Shanghai Shanghai 201401
China
|
|
Employees
|
- |
| Website |
http://www.xykb.com |
| Updated |
07/08/2019 |
| Shanghai Kaibao Pharmaceutical Co., Ltd. engages in the research, development, manufacture and sale of modern Chinese medicine. Its medicines are in the form of injection, tablets, hard capsules, granules, mixture, syrup, oral liquid, and Chinese medicine extraction; such as Tanreqing injection, doxofylline capsule, Captopril sustained-release tablets, and Hydrochloride pioglitazone tablets. The company was founded on April 12, 2000 and is headquartered in Shanghai, China. |
